Health product names often look and sound alike. These similarities sometimes cause clinicians and patients to confuse one drug name for another.
In January 2006, Health Canada’s Guidance for Industry - Drug Name Review: Look-alike Sound-alike (LA/SA) Health Product Names became effective. This guidance stated Health Canada’s expectations and sought to generate consistency in the information submitted by market authorization holders regarding the impact of a proposed name on the safe use of a health product. After analysis, along with requests from industry for greater direction and continuing public concern about medication incidents due to LASA names, suggested that there was an opportunity to improve public health by revising the 2006 guidance on LASA brand name assessment.
For more information click here.